WO2004045651A1 - Compuestos utiles para el diagnostico y seguimiento de enfermedades relacionadas con la formación de fibrilas proteicas amiloides - Google Patents
Compuestos utiles para el diagnostico y seguimiento de enfermedades relacionadas con la formación de fibrilas proteicas amiloides Download PDFInfo
- Publication number
- WO2004045651A1 WO2004045651A1 PCT/ES2002/000537 ES0200537W WO2004045651A1 WO 2004045651 A1 WO2004045651 A1 WO 2004045651A1 ES 0200537 W ES0200537 W ES 0200537W WO 2004045651 A1 WO2004045651 A1 WO 2004045651A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- hydroxyquinoline
- chloro
- complex
- iodo
- iodine
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
- C07D215/24—Oxygen atoms attached in position 8
- C07D215/26—Alcohols; Ethers thereof
- C07D215/30—Metal salts; Chelates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/041—Heterocyclic compounds
- A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K51/0455—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
- A61K51/0478—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group complexes from non-cyclic ligands, e.g. EDTA, MAG3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
- C07D215/24—Oxygen atoms attached in position 8
- C07D215/26—Alcohols; Ethers thereof
- C07D215/28—Alcohols; Ethers thereof with halogen atoms or nitro radicals in positions 5, 6 or 7
Definitions
- the present invention relates to compounds that are useful for the diagnosis and monitoring of diseases related to the formation of amyloid protein fibrils, their use in the diagnosis of said diseases, pharmaceutical compositions containing said compounds and, finally, methods of preparation of said compounds.
- amyloid protein fibrils from precursor proteins. These fibrils can manifest themselves systemically or as localized insoluble deposits.
- amyloid proteins that form fibrils are characterized by being positive for Congo Red, being fibrillar by electron microscopy and having a cross-linked beta structure by X-ray diffraction.
- amyloid protein precursor proteins More than 20 amyloid protein precursor proteins are known being some examples, light and heavy chain immunoglobulins, transthyretin, apolipoprotein Al, gelsolin, lysozyme, the precursor protein of A ⁇ , prion proteins, atrial natriuretic factor, prolactin and insulin.
- Alzheimer's disease Specifically in patients affected by Alzheimer's disease, after post-moriem examination, abnormal accumulations of two types of amyloid protein deposits are observed in brain regions responsible for learning and memory tasks such as the hippocampus. Of these two types, extracellular amyloid plaques are the most characteristic of the disease of Alzheimer's while intracellular neurofibrillar clusters can also be found in other types of neurodegenerative conditions.
- amyloid plaque is formed by dystrophic neurites and other altered astrocytes in addition to microglia that envelops an insoluble fibrillar nucleus. These fibrils are composed of a series of proteins that are generically called ⁇ -amyloid proteins, of which two, A ⁇ 40 and A ⁇ 42, are predominant. It has also been shown that certain transition metals are intrinsic to the composition of ⁇ -amyloid aggregates since ⁇ -amyloid proteins have the ability to bind metals through specific locations for
- the possibility of obtaining functional images of the amount and distribution of amyloid plaques could serve as an important complement to the diagnosis of presymptomatic stages of the disease.
- the development of new neuroimaging techniques in vivo of cerebral amyloid deposits could be much more important for the evaluation of therapeutic alternatives. More specifically, given the need to test therapeutic agents that could inhibit the production or redissolve ⁇ -amyloid proteins and thus reduce or prevent the development of the disease, it is crucial, for example, to be able to make informed decisions on issues such as: what kind of patients they are admitted to clinical trials, when the treatment is applied and how the progress of the therapy is evaluated.
- Non-lnvasive Radiotracer Imaging are very suitable since they allow to visualize and quantify specific events at the molecular level such as those involved here.
- positron emitting isotopes such as 18 F and 11 C
- Positron Emission Tomography PET
- single photon emitting radionuclides such as 99n Tc and 123 l that allow to obtain planar images or images by Single Photon Emission Computerized Tomography
- One of the first strategies has been to conjugate the ⁇ -amiliode protein to protein vectors for which there are specific transporters in the BBB ⁇ Saito Y., etal; Vector- mediated delivery of 125 I-labeled ⁇ -amiloid peptide 1-40 through the blood-brain barrier and binding to Alzheimer 's disease amyloid of the 1-40 / vector complex; Proc. Nati Acad. Sel. USA 92 (1995) 10227-1031). In more recent approaches these vectors are the natural polyamines spermine and putrescine.
- BSB trans, trans-1-bromine 2,5-bis (3-hydroxycarbonyl-4-hydroxy) styryl benzene].
- BSB is capable of binding to amyloid plaques in transgenic mice but also has an affinity for other protein deposits rich in ⁇ folds such as intraneuronal neurofibrils and other bodies such as Lewy that are common to other neurodegenerative diseases such as Parkinson's (Skovronsky DM et to the; in vivo detection of amyloid plaques in a mouse model of Alzheimer 's disease; Proc Natl Acad Sci USA 97 (2000) 7609-7614).....
- US Patent 4 360 509 describes the use of radioactive chelates of indium and 8-hydroxyquinoline to locate inflammatory reactions in warm-blooded animals by non-invasive imaging techniques.
- International patent application WO 00 76966 describes rhodamine derivatives labeled with radioisotopes that are used for the diagnosis of diseases related to the deposition of amyloid protein.
- the applicant After thorough and laborious investigation, the applicant has prepared some compounds that due to their structure are capable of interacting with the amyloid protein fibrils, including those that manifest as amyloid plaques and affect the central nervous system, and that surprisingly are also able to pass through the blood brain barrier. Said compounds are, therefore, useful for the diagnosis and monitoring of diseases related to the formation of amyloid protein fibrils and, in addition, do not present the problems of the compounds and methods employed so far in the state of the art such as the degradation of said compounds, their low permeability to the blood brain barrier, their low specificity, etc. With these compounds it is therefore possible to carry out a diagnosis or follow-up of the diseases referred to above in animals, transgenic animals and, in particular, in man.
- X represents O, S
- A represents N or NR 4 ;
- B represents CR 5 , NR 5 or N;
- D represents CR 6 , NR 6 or N •
- E represents CR 7 , NR 7 or N with the proviso that the ring containing group A has a maximum of two nitrogen atoms in its structure;
- Ri, R 2 , R 3 , R 4 , Rs, Re and R7 each independently represents a radioactive isotope, H, halogen or a radical that optionally has a radioactive isotope with said radical being selected from: dC 6 alkyl, OH, CrC 6 polyhydroxyalkyl, dC 6 alkoxy, dC 6 alkoxyalkyl, (CH 2 )
- R is H, an alkyl group , 6 AD or AD 6 alkyloxy; with the proviso that only one of R1, R 2 , R3, R 4 , Rs, Re, R 7 , X and Y is or presents a radioactive isotope; in the preparation of a composition for the diagnosis and / or monitoring of diseases related to the formation of amyloid protein fibrils, in particular those that manifest as amyloid plaques and affect the central nervous system.
- a second aspect of the present invention consists in the use of the compounds of general formula II
- Line 11111111 represents a coordination link;
- A represents N or NR 4 ;
- B represents CR 5 , NR 5 or N;
- D represents CR S , NR 6 or N
- E represents CR 7 , NR 7 or N
- the lines represent a single or double bond
- Rx, R 2 , R 3 , R 4 , R 5 , R 6 and R 7 each independently represents a radioactive isotope, H, halogen or a radical that optionally has a radioactive isotope with said radical being selected from: C 1 -C 6 alkyl, OH, C, -C 6 polyhydroxyalkyl, C r C 6 alkoxy, dC 6 alkoxyalkyl, (CH 2 ) q-
- OR ' where q is 1, 2 or 3, CF 3 , CH 2 -CH 2 F, 0-CH 2 -CH 2 F, CH 2 -CH 2 -CH 2 F, CN, NO 2 , O (CO) R ', OR', SR ', COOR' -SO 3 H, (CH 2 ) r-C0 2 R ", (CH 2 ) r-CO-R ', where r is 1, 2 or 3, and Rph, where Rph represents an unsubstituted or substituted phenol group, the possible substituents of the phenol group being any of the meanings of RR 7 except for a phenol group;
- R ' is H or a C ⁇ alkyl group
- R ⁇ R 2 , R 3 , R 4 , R 5 , R s , R 7 , X, Y or Z is or present a radioactive isotope
- a third aspect of the present invention consists in the use of the compounds of general formula III formula III
- X represents O, S
- Z represents a cation of a rare metal or earth that may or may not be radioactive
- Line 11111111 represents a coordination link
- A represents N or NR 4 ;
- B represents CR S , NR 5 or N
- D represents CR 6 , NR 6 or N
- Ri, R 2 , R 3 , R 4 , Rs, Re and R7 each independently represents a radioactive isotope, H, halogen or a radical that optionally has a radioactive isotope with said radical being selected from: dC 6 alkyl, OH, dC 6 polyhydroxyalkyl, dC 6 alkoxy, C ⁇ -C 6 alkoxyalkyl, (CH 2 ) q- OR ⁇ where q is 1, 2 or 3, CF 3 , CH 2 -CH 2 F, O-CH 2 -CH 2 F, CH 2 -CH 2 -CH 2 F, CN, NO 2 , O (CO) R ', OR', SR ', COOR' -SO 3 H, (CH 2 ) r-CO 2 R ", (CH 2 ) r -CO-R ', where r is 1, 2 or 3, and Rph, where Rph represents a non-phenol group substituted or substituted, the possible substituents of the phenol
- R ' is H or a C1.3 alkyl group
- R " is H, a dC 6 alkyl or dC 6 alkyloxy group
- diseases related to the formation of amyloid protein fibrils are understood as diseases such as Alzheimer's, Parkinson's, Huntington, Creutzfel-Jacob, fibrosis cystic, late onset diabetes, motor neuron disease, Mediterranean fever, Muckle-Wells syndrome, idiopathic myeloma, amyloid polyneuropathy, amyloid cardiomyopathy, senile systemic amyloidosis, hereditary cerebral hemorrhage with amoloidosis, Down syndrome, Creutzfeldt-Jacob disease , Kuru, Gerstmann-Straussler-Schienker syndrome, medullary thyroid carcinoma, valvular amyloid deposits, amyloidosis in dialysis patients, myositis with inclusion bodies, muscle deposits of amyloid, Sickie Cell Parkinson's anemia, type 2 diabetes, among others .
- a fourth aspect of the invention relates to compounds having the following structures:
- X represents O, S
- A represents N or NR 4 ;
- B represents CR 5 , NR 5 or N;
- D represents CR 6 , NR 6 or N
- RR 2 , R 3 , R 4 , R 5 , R 6 and R 7 each independently represents a radioactive isotope, H, halogen or a radical that optionally has a radioactive isotope with said radical being selected from: C, -C 6 alkyl , OH, CC 6 polyhydroxyalkyl, C r C 6 alkoxy, C
- OR ' where q is 1, 2 or 3, CF 3 , CH 2 -CH 2 F, 0-CH 2 -CH 2 F, CH 2 -CH 2 -CH 2 F, CN,
- R ' is H or a group C ,. 3 alkyl
- R is H, a CC 6 alkyl or dC ⁇ alkyloxy group; with the proviso that R. ,, R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , X and Y are not all simultaneously H , and with the proviso that only one of R-, R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , X and Y is or presents a radioactive isotope;
- X represents O, S
- Z represents a cation of a rare metal or earth that may or may not be radioactive
- Line iiiiiiiiiii represents a coordination link
- A represents N or NR 4 ;
- B represents CR 5 , NR 5 or N
- D represents CR 6 , NR 6 or N
- Ri, 2, R3, R4, Rs, Re and R7 each independently represents a radioactive isotope, H, halogen or a radical that optionally has a radioactive isotope, said radical being selected from: C Ce alkyl, OH, dC 6 polyhydroxyalkyl, CC 6 alkoxy, dC 6 alkoxyalkyl, (CH 2 ) q- OR ', where q is 1, 2 or 3, CF 3 , CH 2 -CH 2 F, 0-CH 2 -CH 2 F, CH 2 -CH 2 -CH 2 F, CN, NO, O (CO) R ', OR', SR ', COOR' -SO 3 H, (CH 2 ) r-CO 2 R ", (CH 2 ) r-CO-R ⁇ where r is 1, 2 or 3, and Rph, where Rph represents an unsubstituted or substituted phenol group, the possible substituents of the phenol group being any of the meanings of R 1 -
- X represents O, S
- Z represents a cation of a rare metal or earth that may or may not be radioactive
- Line 11111111 represents a coordination link
- A represents N or NR 4 ;
- B represents CR 5 , NR 5 or N
- D represents CR 6 , NR S or N
- R is H, a group C r C 6 alkyl or CC 6 alkyloxy; with the proviso that Rx, R 2 , R 3 , R 4 , R 5 , R 5 , R 7 , X and Y are not all simultaneously H , and with the proviso that only one of R 1; R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , X, Y or Z is or presents a radioactive isotope; and with the proviso that when
- A is N
- X is O, and m, n and p are all 1, then R. ,, R 2 and R 3 are not all H.
- Preferred compounds to be used in the diagnosis and monitoring of diseases related to the formation of amyloid protein fibrils are selected from the following:
- the compounds of the present invention are prepared according to methods known in the state of the art. So:
- the compounds of formula I will be prepared according to a method comprising reacting a quinoline derivative: a) with an aromatic electrophilic halogenation reagent incorporating a radioactive halogen atom, or; b) with a halogenated radioactive derivative to effect an aromatic nucleophilic substitution reaction.
- the compounds of formula II are prepared according to a method comprising reacting a quinoline derivative: a) with a metal or rare earth cation, or, b) with a radioactive isotope of these elements. such that the metal or rare earth cation or the radioactive isotope of these elements is in its proper oxidation state to give rise to the corresponding chelation product of formula II.
- the compounds of formula III are prepared according to conventional methods known in the state of the art. Preferred methods comprise reacting a quinoline derivative with: a) a rare metal or earth cation, or b) a radioactive isotope of these elements in their suitable oxidation state to give rise to the corresponding chelation product defined in the formula III.
- Preferred methods comprise reacting a quinoline derivative with: a) a rare metal or earth cation, or b) a radioactive isotope of these elements in their suitable oxidation state to give rise to the corresponding chelation product defined in the formula III.
- a solution of 1-3 mCi of Na 125 l is introduced into a 10 mL balloon and evaporation is dried at 100 ° C under a stream of nitrogen.
- the corresponding 7-iodoquinoline (100 mg) dissolved in 2 mL of a suitable solvent is added.
- the balloon is attached to a reflux condenser and the bath temperature is increased.
- the reaction mixture is stirred under a nitrogen atmosphere for a certain time and allowed to cool. Water is added and the product that is collected by filtration is washed thoroughly with water. It is recrystallized and purity is established by thin layer radiochromatography.
- EXAMPLE 3 Synthesis of 5-chloro-8-hydroxy-7-r 123 Hvodoquinoline from the organostanic derivative using chloramine T.
- a solution of the trimethyltannic derivative described in example 2 200-300 ug
- 300 uL of ethanol is added [ 123 L] sodium iodide (2-20 mCi) followed by chloramine T (100 ug) in 1N HCI (100 uL).
- the reaction is stopped with an aqueous solution of metabisulfite (50 mg / mL, 100 uL) and injected into the RP-HPLC.
- the fraction of the radioiodinated derivative that is obtained with 98% radiochemical purity is collected.
- the radioiodinated derivative is obtained from the tributyltannic derivative prepared analogously to the organostanic described in example 2 by suspension in methanol and treatment with Na 131 1 and hydrogen peroxide at room temperature, as described below.
- the reaction takes place by adding 50 uL of H 2 O 2 (3% w / v) to a mixture consisting of 50 uL of the tributyltin derivative (100 ug / 50 uL EtOH), 1.5 mCi of [ 125 l] sodium iodide (specific activity 2,200 Ci / mmol) and 100 uL of 1 N HCI in a sealed vial.
- the reaction is stirred at room temperature for 10 min and is terminated after adding 100 uL of a saturated NaHSO 3 solution. It is neutralized with sodium bicarbonate and extracted with ethyl acetate.
- the extract is dried by passing the solution through an anhydrous Na 2 SO 4 column and the solvent is evaporated by a stream of nitrogen.
- the crude is purified by HPLC obtaining a radiochemical purity greater than 85%.
- the fractions are taken to dryness and the residue is reextracted with EtOAc.
- the different EtOAc extracts are concentrated under nitrogen atmosphere to dryness.
- the residue is dissolved in EtOH.
- the radiochemical purity of the final product is greater than 98% (by HPLC)
- EXAMPLE 5 Synthesis of 5-chloro-8-hydroxy-7-f 131 ⁇ vodoquinoline using chloramine T.
- a solution of 30 nmol of 5-chloro-8-hydroxyquinoline in 30 uL of ethanol is added to 10 mCi of [ 125 l] sodium iodide (4.5 ug, 330 Ci / mmol, 30 nmol) in 0.001 N NaOH (30 uL) .
- a solution of chloramine T (13 ug, 50 nmol) in water (10 uL) is added.
- the mixture is heated at 60 ° C for 45 min.
- 100 uL of 0.1 N NH 4 CI are added and extracted with ether.
- the reaction result is analyzed by thin layer chromatography (Silica gel, Merck F254) in the appropriate eluent and proceeds as in the previous example.
- EXAMPLE 8 Preparation of 5-chloro-8-hydroxy-7-f 125 nyodoquinoline using Yodo-beads.
- the necessary amount of Yodo-beads is added to a solution of Na 125 l in buffer solution at a concentration of 1mCi per 100 ug of product to iodine.
- between 5 and 500 ug of the phenolic derivative dissolved in the same buffer solution is added thereto. It is allowed to react between 2 and 15 min at room temperature. The reaction is stopped by separating the iodine beads from the solution by decantation.
- the iodine beads are washed with the buffer solution in order to recover all the radioiodinated derivative.
- the radiochemical performance is purified and determined by chromatographic methods as described in previous examples.
- EXAMPLE 10 Preparation of 5-chloro-7-f 18 F1fluoro-8-hydroxyquinoline by direct radiofluorination.
- the direct radiofluorination of 100 umol of the phenolic derivative 5-chloro-8-hydroxyquinoline is carried out by dissolving the compound in an acid mixture trifluoroacetic and glacial acetic acid (1: 1) through which freshly prepared acetyl hypofluorite ([ 8 F] CH 3 -COOF) is burghed. The solvent is evaporated and the residue is purified by HPLC.
- Radioactive fluoride [ 18 F] is transferred to a 5mL borosilicate reaction vial and azeotropically dried with acetonitrile in the presence of 4.0 mg of K 2 C0 3 and 14.6 mg of Kryptofix 2.2.2 ®.
- the fluorinated precursor derivative dissolved in 0.5 mL of DMSO is added and the isotopic exchange reaction is carried out by heating at 110, 130 and 160 ° C for 0-30 min to optimize the reaction.
- the purification of the radiofluorinated derivative is carried out by reverse phase HPLC. The corresponding fractions are collected and concentrated under reduced pressure.
- the starting product dissolved in 600 uL of ethanol is added to 100 uL of a solution A (containing 200 umol of SnSO 4.2 , 2 mmol of gentisic acid, 2 mmol of citric acid monohydrate 10 uL of glacial acetic acid dissolved in acetic acid 10%), 25 uL of a solution B (containing 400 umol of CuSO 4 .5H 2 O dissolved in 10 mL of water) and 65 uL of glacial acetic acid.
- the vial is placed in an ultrasonic bath for 15 min, and 10 uL of Na 123 is added ! (approx. 1mC ⁇ ).
- N 2 is passed through the mixture and heated at 60 ° C for 1 h. It is allowed to cool to room temperature and the reaction crude is purified by HPLC.
- Example 1 The characterization and isolation of the radiolabelled product is carried out as in Example 1 1.
- EXAMPLE 14 Synthesis of 5-cioro-7- ⁇ 8 F1fluoro-8-hydroxyquinoline from the unprotected precursor.
- the electrophilic radioiodination agent [ 18 F] CH 3 COOF prepared from 100 umol [ 18 F] F 2 , or [ 18 F] OF 2 (100 umol), is bubbled into a solution (101 umol) in 10 mL of Freon-11 (CFCI 3 ) of the trimethyl stannic derivative 5-chloro-8-hydroxy-7- trimethylstannyl-quinoline or 5-chloro-8-hydroxy-7-tributylstanylquinoline at room temperature for 10 min.
- the solvent is evaporated at 50 ° C with a stream of nitrogen and the residue is dissolved in 10 mL of methylene chloride and transferred to a chromatographic column packed with Na 2 S 2 0 3 (2.5 cm) and silica gel (9.5 cm) that has been previously balanced with ether. It elutes with ether.
- the solvent is evaporated and purified by semi-preparative HPLC.
- the electrophilic radiofluorination agent [ 18 F] CH 3 COOF prepared from 100 umol [ 18 F] F 2 , of s F] OF 2 (100 umol), is bubbled into a solution (101 umoi) in 10 mL of Freon-11 (CFCI 3 ) of the trimethyl stannic derivative 5-chloro-8-t- butoxycarbonyloxy-7-trimethylstannilquinoline or 5-chloro-8-t-butoxycarbonyloxy-7- tributyl stanylquinoline at room temperature for 10 min.
- CFCI 3 Freon-11
- the solvent is evaporated at 50 ° C with a stream of nitrogen and the residue is dissolved in 10 mL of methylene chloride and transferred to a chromatographic column packed with Na 2 S 2 O 3 (2.5 cm) and silica gel (9.5 cm) that has been previously balanced with ether. It elutes with ether.
- the solvent is evaporated and the derivative is hydrolyzed in the presence of a 48% solution of hydrobromic acid at 130 ° C for 10 min. After cooling, the reaction mixture is partially neutralized with a 3N NaOH solution and purified by HPLC.
- methyl trifluoromethanesulfonate methyl trifluoromethanesulfonate.
- the solution is stirred for 1h at room temperature under a nitrogen atmosphere and then diluted with 100 mL of water.
- the product is extracted with dichloromethane, the solvent is evaporated and triturated with diethyl ether.
- about 2.0-3.5 mg (6.5-11.3 umol) of the derived methyl trifluoromethanesulfonate are dissolved in 600 uL of freshly distilled DMSO and added directly to the tube containing the anhydrous complex of K [ 8 F] F-K222 .
- the tube is heated in a heating block at 145-150 ° C without stirring for two minutes or placed in a 100 W microwave oven for 1 min.
- the reaction mixture is allowed to cool and diluted with 3 mL of water and filtered through a C18 Sep Pack cartridge.
- the cartridge is washed with 3.0 mL of water and partially dried during 0.5 min applying a stream of nitrogen.
- the radiofluorinated derivative is eluted from the cartridge with DCM (3 mL) followed by two washes over 1 mL each.
- EXAMPLE 17 Synthesis of clioquinol glycoconjugate, 5-chloro-8-yl-7-iodo-quinolin-beta-D-qlucuronic acid sodium salt.
- the reaction is diluted with dichloromethane, filtered and the solvent is removed under reduced pressure.
- the glycoconjugate is purified by flash column chromatography. (TLC: CH 2 CI 2 / MeOH 99/1, eluent: CH 2 CI 2 / MeOH 99.5 / 0.5).
- Radioiodination of clioquinol qlucuronide with Yodoqen TM Synthesis of 5-chloro-8-hydroxy-7-r 131 ⁇ vodoquinoline qlucuronide.
- EXAMPLE 19 Radioiodination of clioquinol glucuronide with chloramine T: Synthesis of 5-chloro-8-hydroxy-7- ⁇ 125 ⁇ vodoquinoline glucuronide.
- a solution of 4 mg / mL of chloramine T in 50 mM of disodium phosphate is prepared, at pH 7.
- the vial is closed and 25 uL of the chloramine T solution is added and stirred for 30 sec. Once the reaction is finished, 100 uL of 12.6 mM sodium metabisulfite is added. Stir for 10 sec.
- the reaction product is purified by gel filtration using a Sephadex G-25 or G-50 column.
- Radioiodination of clioguinol glucuronide with iodine-beads Synthesis of glucuronide of 5-chloro-8-hydroxy-7-r 125 llvodoguinoline.
- Indian [ 111 ln] chloride trihydrate ( 111 lnCl 3 .3H 2 0.37 g, 5.0 mmol) and 5,7-dichloro-8-hydroxyquinoline (2.14 g, 10 mmol) are dissolved in ethanol (200 L), the solution is concentrated to dryness under reduced pressure. The yellow crude obtained is Recrystallize from ethanol after the addition of water to give the Indian [ 111 ln] complex of 5,7-dichloro-8-hydroxyquinoline.
- EXAMPLE 22 Synthesis of the f 67 Ga1 gallium queiate of 8-hydroxyquinoline.
- [ 67 Ga] gallium chelate is prepared by adding [ ⁇ 7 Ga] gallium trichloride ( 67 GaCI 3 ) dissolved in a 0.05M solution of HCI to a 7 mM aqueous solution of 8-hydroxyquinoline at pH 3.5. After stirring for 25 minutes, the pH is increased to 6. Extraction of the product with chloroform leads to the chelate obtained with a
- 0.3 mL of a solution (20 mg, 0.11 mmol in 10 mL of 1 N HCI) of SnCI 2 is added and the pH is adjusted again with 0.1 N NaOH. It is stirred for 5 min and 80 uCi of technetium-99m are added in the form of sodium pertechnetate. Chelate is obtained by extraction with chloroform with a yield greater than 90%.
- a solution of [ 64 Cu] copper (II) chloride ( 64 CuCl 2 ) is diluted 10 times with a 0.1 M ammonium acetate buffer solution of pH 5.5.
- the [ 64 Cu] copper acetate is added to 8-hydroxyquinoline and the final volume is adjusted to 1.0-1.5 mL with the buffer solution. After incubating at room temperature for 45 min. The Extraction with chloroform of the product derived from 64 Cu leads to the chelate that is obtained with a 90% yield.
- EXAMPLE 25 Preparation of the chelate of f s7 Cul copper of 8-hydroxyquinoline.
- the [ 67 Cu] copper derivative is filtered through a polytetrafluoroethylene (PFTE) membrane. Radiochemical purity is determined by thin layer chromatography on silica gel plates eluting with ethanol.
- PFTE polytetrafluoroethylene
- METHOD B Radio chelation of 5-chloro-8-hydroxyquinoline copper chelate.
- a solution of 30 nmol of 5-chloro-8-hydroxyquinoline copper chelate in 30 uL of ethanol is added to 10 mCi of [ 125 l] sodium iodide (4.5 ug, 330 Ci / mmol, 30 nmol) in 0.001 N NaOH (30 uL).
- a solution of chloramine T (13 ug, 50 nmol) is added. in water (10 uL). The mixture is heated at 60 ° C for 45 min. Are added 100 uL of 0.1 N NH 4 CI and extracted with ether. The product is analyzed by thin layer chromatography (Silica gel, Merck F254) in the appropriate eluent.
- EXAMPLE 27 Synthesis of zinc chelates of 5-chloro-8-hydroxy-7- ⁇ 12S llvodoquinoline.
- METHOD B Radioiodination of the 5-chloro-8-hydroxyquinoline zinc chelate.
- a solution of 5-chloro-8-hydroxyquinoline zinc chelate in 30 uL of ethanol is added to 10 mCi of p 25 l] sodium iodide (4.5 ug, 330 Ci / mmol, 30 nmol) in 0.001 N NaOH (30 uL ).
- a solution of chloramine T (13 ug, 50 nmol) in water (10 uL) is added. The mixture is heated at 60 ° C for 45 min. 100 uL of 0.1 N NH 4 CI are added and extracted with ether.
- the reaction product is analyzed by thin layer chromatography (Silica gel, Merck F254) in the appropriate eluent.
- the radioactive derivative 5-chloro-8-hydroxy-7- [ 123 L] iodoquinoline is injected into transgenic mice (Tg2576) and control mice via the jugular vein under anesthesia using a 30 g syringe. A series of controls and transgenic mice are examined. After 2, 4, 6 h of the Intravenous Injection, the brains of each mouse are removed, cooled rapidly with carbonic snow and sectioned using a Mokron HM 505E cryostat apparatus by placing them in glass sheets and dried at room temperature. For film autoradiography, the sheets are placed in a MICROM optical densitometer, obtaining grayscale images of the distribution of the radiopharmaceutical in histological sections. The measured optical density is expressed as a percentage (%) of the maximum. Images were obtained with optimal detection of amyloid plaques in the brain of mice.
- MicroPET images of transgenic mice All animal experiments were done according to the established animal protocol.
- Transgenic mice (Tg2576) were anesthetized via intravenous injection with a solution of 40 uL of ketamine and xylazine (4: 1) before injection of the radiolabeled tracer with 18 F: 5- [ 18 F] fluoro-8-hydrox ⁇ - 7-iodoquinoline.
- the mice were placed supine and were scanned using the microPET.
- a dynamic microPET study was carried out using 15 planes and 15 to 16 frames (dynamic sequence: 6x 30 s, 4x 1 min, 2x5 min, 2x 10 min, and 1-2 x 20 min) for a total acquisition time of 55 -77 min.
- the images were reconstructed using the appropriate algorithms (Filter-back projection algorithm) and a cutoff frequency of 0.5.
- the images were reconstructed by filtered iteration resulting in an image resolution of 1.8 mm and a volumetric resolution of approximately 6 mm 3 .
- the transverse planes were reoriented to obtain the coronal and axial sections of the mice's brain. Regional uptake is expressed in activity per gram of tissue. The images showed adequate detection of the amyloid plaques in the mice's brain.
- the tracers (with detectable radionuclides via SPECT) (1-5 uCi) dissolved 100 ul of PBS or in the appropriate solvent were injected via the tail vein.
- SPECT images were obtained after 4.5 h of administration of the 5-chloro-8-hydroxy-7-p 23 l] iodoquinoline tracer by means of a double-head chamber (MULTISPECT II, Siemens Medical Systems) equipped with high-resolution parallel collimators for low energies, using an energy window centered on the photopic energy of the corresponding radionuclide (159KeV for 123 l).
- Sources of 57 Co placed on the animal's head were used to facilitate reconstruction by anatomical references.
- 120 projections were obtained in a 360 degree rotation acquired in a 64x64 matrix.
- Two simultaneous acquisitions are made, one using a window of 20% of energy centered at 159 KeV for 123 1 and another of 4% of energy centered at 122 KeV for the markers of 57 Co.
- the total exploration time was of about 40 minutes.
- SPECT images were reconstructed using a filtered back projection algorithm. Attenuation correction was performed using Chang's algorithm.
- the semi-quantitative analysis of the collection was carried out by comparing the average / pixel accounts in the region of interest with the average / pixel accounts of control regions. The results were compared with those obtained in macroautoradlographies. The images showed the distribution of amyloid plaques in the brains of mice.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Physics & Mathematics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Optics & Photonics (AREA)
- Neurosurgery (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Quinoline Compounds (AREA)
- Saccharide Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims
Priority Applications (8)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/534,749 US20080063599A1 (en) | 2002-11-18 | 2002-01-14 | Compounds Which Can Be Used To Diagnose And Monitor Diseases Associated With The Formation Of Amyloid Protein Fibrils |
ES02785448T ES2297024T3 (es) | 2002-11-18 | 2002-11-18 | Compuestos utiles para el diagnostico y seguimiento de enfermedades asociadas con la formacion de fibrilas proteicas amiloides. |
PCT/ES2002/000537 WO2004045651A1 (es) | 2002-11-18 | 2002-11-18 | Compuestos utiles para el diagnostico y seguimiento de enfermedades relacionadas con la formación de fibrilas proteicas amiloides |
JP2004552734A JP2006514928A (ja) | 2002-11-18 | 2002-11-18 | アミロイドタンパク質線維の形成に関連する疾患を診断および監視するために利用できる化合物 |
DE60223729T DE60223729T2 (de) | 2002-11-18 | 2002-11-18 | Verbindungen zur diagnose und überwachung von erkrankungen in zusammenhang mit der bildung von amyloidfibrillen |
EP02785448A EP1563852B1 (en) | 2002-11-18 | 2002-11-18 | Compounds which can be used to diagnose and monitor diseases associated with the formation of amyloid protein fibrils |
CA002505506A CA2505506C (en) | 2002-11-18 | 2002-11-18 | Compounds which can be used to diagnose and monitor diseases associated with the formation of amyloid protein fibrils |
AU2002350751A AU2002350751C1 (en) | 2002-11-18 | 2002-11-18 | Compounds which can be used to diagnose and monitor diseases associated with the formation of amyloid protein fibrils |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/ES2002/000537 WO2004045651A1 (es) | 2002-11-18 | 2002-11-18 | Compuestos utiles para el diagnostico y seguimiento de enfermedades relacionadas con la formación de fibrilas proteicas amiloides |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2004045651A1 true WO2004045651A1 (es) | 2004-06-03 |
Family
ID=32319763
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/ES2002/000537 WO2004045651A1 (es) | 2002-11-18 | 2002-11-18 | Compuestos utiles para el diagnostico y seguimiento de enfermedades relacionadas con la formación de fibrilas proteicas amiloides |
Country Status (8)
Country | Link |
---|---|
US (1) | US20080063599A1 (es) |
EP (1) | EP1563852B1 (es) |
JP (1) | JP2006514928A (es) |
AU (1) | AU2002350751C1 (es) |
CA (1) | CA2505506C (es) |
DE (1) | DE60223729T2 (es) |
ES (1) | ES2297024T3 (es) |
WO (1) | WO2004045651A1 (es) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2005216949B2 (en) | 2004-02-24 | 2011-09-22 | The General Hospital Corporation | Catalytic radiofluorination |
US9017724B2 (en) | 2004-02-24 | 2015-04-28 | The General Hospital Corporation | Catalytic radiofluorination |
US8257680B1 (en) | 2004-02-24 | 2012-09-04 | The General Hospital Corporation | Catalytic radiofluorination |
EP2289564A3 (en) | 2006-09-08 | 2012-11-14 | Piramal Imaging SA | Derivatives of aniline as precursors for F18-labeling |
MX2010010314A (es) | 2008-03-21 | 2011-04-12 | Gen Hospital Corp | Compuestos y composiciones para la deteccion y el tratamiento de la enfermedad de alzheimer y trastornos relacionados. |
WO2017027064A1 (en) | 2015-08-12 | 2017-02-16 | The General Hospital Corporation | 8-hydroxyquinoline derivatives as diagnostic and therapeutic agents |
CN110759952B (zh) * | 2019-09-27 | 2021-04-20 | 广西师范大学 | 基于8-甲氧基喹啉构筑的钴配合物及其制备方法和应用 |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4360509A (en) * | 1979-12-19 | 1982-11-23 | Byk-Mallinckrodt Cil B.V. | Vivo radioassay process |
WO1998006403A1 (en) * | 1996-08-13 | 1998-02-19 | P.N. Gerolymatos S.A. | Use of the chelating agent clioquinol for the manufacture of a pharmaceutical composition for the treatment of alzheimer's disease |
JPH11204260A (ja) * | 1998-01-19 | 1999-07-30 | Mitsubishi Chemical Corp | キノリノール誘導体、その金属錯体およびそれを用いた有機電界発光素子 |
US20020025944A1 (en) * | 2000-04-28 | 2002-02-28 | Bush Ashley I. | Use of clioquinol for the therapy of Alzheimer's disease |
WO2002024652A1 (en) * | 2000-09-22 | 2002-03-28 | Pharmacia & Upjohn Company | Compounds and methods for diagnosing and treating amyloid-related conditions |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4279887A (en) * | 1978-11-29 | 1981-07-21 | Medi-Physics, Inc. | Amides useful as brain imaging agents |
US5045303A (en) * | 1985-05-17 | 1991-09-03 | Neorx Corporation | Radiohalogenated small molecules for protein labeling |
-
2002
- 2002-01-14 US US10/534,749 patent/US20080063599A1/en not_active Abandoned
- 2002-11-18 JP JP2004552734A patent/JP2006514928A/ja active Pending
- 2002-11-18 AU AU2002350751A patent/AU2002350751C1/en not_active Ceased
- 2002-11-18 WO PCT/ES2002/000537 patent/WO2004045651A1/es active IP Right Grant
- 2002-11-18 ES ES02785448T patent/ES2297024T3/es not_active Expired - Lifetime
- 2002-11-18 CA CA002505506A patent/CA2505506C/en not_active Expired - Fee Related
- 2002-11-18 EP EP02785448A patent/EP1563852B1/en not_active Expired - Lifetime
- 2002-11-18 DE DE60223729T patent/DE60223729T2/de not_active Expired - Lifetime
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4360509A (en) * | 1979-12-19 | 1982-11-23 | Byk-Mallinckrodt Cil B.V. | Vivo radioassay process |
WO1998006403A1 (en) * | 1996-08-13 | 1998-02-19 | P.N. Gerolymatos S.A. | Use of the chelating agent clioquinol for the manufacture of a pharmaceutical composition for the treatment of alzheimer's disease |
JPH11204260A (ja) * | 1998-01-19 | 1999-07-30 | Mitsubishi Chemical Corp | キノリノール誘導体、その金属錯体およびそれを用いた有機電界発光素子 |
US20020025944A1 (en) * | 2000-04-28 | 2002-02-28 | Bush Ashley I. | Use of clioquinol for the therapy of Alzheimer's disease |
WO2002024652A1 (en) * | 2000-09-22 | 2002-03-28 | Pharmacia & Upjohn Company | Compounds and methods for diagnosing and treating amyloid-related conditions |
Non-Patent Citations (3)
Title |
---|
DATABASE CAPLUS [online] accession no. STN Database accession no. 1999:472241 * |
DATABASE CAPLUS [online] ANDO ET AL.: "Rapid synthesis of I-131 and I-125 labeled chinoform", accession no. STN Database accession no. 1975:31226 * |
RADIOISOTOPES, vol. 23, 1974, pages 6 - 9 * |
Also Published As
Publication number | Publication date |
---|---|
AU2002350751A1 (en) | 2004-06-15 |
CA2505506A1 (en) | 2004-06-03 |
AU2002350751B2 (en) | 2006-04-06 |
CA2505506C (en) | 2008-07-08 |
EP1563852B1 (en) | 2007-11-21 |
DE60223729T2 (de) | 2008-10-30 |
AU2002350751A8 (en) | 2004-06-15 |
EP1563852A1 (en) | 2005-08-17 |
AU2002350751C1 (en) | 2006-11-16 |
JP2006514928A (ja) | 2006-05-18 |
ES2297024T3 (es) | 2008-05-01 |
US20080063599A1 (en) | 2008-03-13 |
DE60223729D1 (de) | 2008-01-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101355940B (zh) | 用于检测具有至少一种促淀粉样变蛋白的淀粉样沉积物的体内或体外方法 | |
JP5680409B2 (ja) | 前立腺特異膜抗原(psma)の標識阻害剤、生物学的評価およびイメージング剤としての使用 | |
ES2427963T3 (es) | Uso de derivados de tioflavina radiomarcados en formación de imágenes de amiloide para evaluación de las terapias antiamiloide | |
EP2218464A1 (en) | Compounds for non-invasive measurement of aggregates of amyloid peptides | |
KR20140052027A (ko) | 알부민-결합 개체들의 폴레이트 공액체들 | |
CN109475648B (zh) | 用于成像tau蛋白聚集体的化合物 | |
AU2008363871A1 (en) | Fluorinated benzothiazole derivatives, preparation method thereof and imaging agent for diagnosing Altzheimer's disease using the same | |
Serdons et al. | Synthesis and evaluation of a 99mTc-BAT-phenylbenzothiazole conjugate as a potential in vivo tracer for visualization of amyloid β | |
Neumaier et al. | Synthesis and evaluation of 18F-fluoroethylated benzothiazole derivatives for in vivo imaging of amyloid plaques in Alzheimer's disease | |
BR112020014594A2 (pt) | composições de diagnóstico para imageamento pet, método para fabricar composição de diagnóstico e seu uso em diagnóstico | |
EP2198040B1 (en) | In vivo imaging of myelin | |
Nguyen et al. | IBETA: A new aβ plaque positron emission tomography imaging agent for Alzheimer’s disease | |
ES2297024T3 (es) | Compuestos utiles para el diagnostico y seguimiento de enfermedades asociadas con la formacion de fibrilas proteicas amiloides. | |
JP2024502341A (ja) | デュアルモード放射性トレーサーおよびその療法 | |
KR20090087037A (ko) | 오론 유도체 함유 진단용 조성물 | |
JP2021534077A (ja) | Tspo結合剤 | |
US9205156B2 (en) | Molecular imaging agents | |
BR112014023988B1 (pt) | método de preparação de um conjugado de tiazolidina-açúcar, composição de conjugado de etilenodicisteína-açúcar e seu uso | |
Nguyen et al. | [124I] BETA, a new beta-amyloid plaque PET imaging agent for Alzheimer's disease | |
BR112020014949B1 (pt) | Método para preparação de um composto de formação de imagem | |
WO2019222454A1 (en) | Styrylbenzothiazole derivatives and uses in imaging | |
WO2011124713A1 (en) | Labelled huprine derivatives and their use in medical imaging | |
Terry et al. | George P. Keeling, Billie Sherin, Jana Kim, Belinda San Juan, Tilmann Grus, b Thomas R. Eykyn, Frank Rösch, b Gareth Smith, c Philip J. Blower | |
Keeling et al. | tracer with Facile Radiolabelling and Broad Calcium Mineral Affinity |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SC SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2505506 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2004552734 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2002785448 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2002350751 Country of ref document: AU |
|
WWP | Wipo information: published in national office |
Ref document number: 2002785448 Country of ref document: EP |
|
WWG | Wipo information: grant in national office |
Ref document number: 2002785448 Country of ref document: EP |